

PATENT COOPERATION TREATY


PCT

From the INTERNATIONAL SEARCHING AUTHORITY

To:	MONEY	E
D. YOUNG	ORDER	
Attn. Massimo Antonio	DIARY	10-07-03
21 New Fetter Lane	REC'D	
London EC4A 1DA	12 JUN 2003	
UNITED KINGDOM		
ANSO		
ENTRY		
FOR	FOR	ATM

INVITATION TO PAY ADDITIONAL FEES

(PCT Article 17(3)(a) and Rule 40.1)



Applicant's or agent's file reference P010833WO ATM	PAYMENT DUE within 30 xxxx days from the above date of mailing
International application No. PCT/GB 02/ 01457	International filing date (day/month/year) 25/03/2002
Applicant THE UNIVERSITY OF EDINBURGH	

1. This International Searching Authority

- (i) considers that there are 07 (number of) inventions claimed in the international application covered by the claims indicated ~~below~~ on the extra sheet:

and it considers that the international application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated ~~below~~ on the extra sheet:

- (ii) ☒ has carried out a partial international search (see Annex) ☐ will establish the international search report on those parts of the international application which relate to the invention first mentioned in claims Nos.:
see annex

- (iii) will establish the international search report on the other parts of the international application only if, and to the extent to which, additional fees are paid


2. The applicant is hereby invited, within the time limit indicated above, to pay the amount indicated below:

EUR 945,00 x 06 = EUR 5.670,00
 Fee per additional invention number of additional inventions total amount of additional fees

Or, _____ x _____ = _____

The applicant is informed that, according to Rule 40.2(c), the payment of any additional fee may be made under protest, i.e., a reasoned statement to the effect that the international application complies with the requirement of unity of invention or that the amount of the required additional fee is excessive.

3. ☒ Claim(s) Nos. see annex have been found to be unsearchable under Article 17(2)(b) because of defects under Article 17(2)(a) and therefore have not been included with any invention.

Name and mailing address of the International Searching Authority
 European Patent Office, P.B. 5818 Patentlaan 2
 NL-2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Sylvia Hermier

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-9, 12 (partially), 13-22, 25 (partially), 26, 27-30 (partially), 31, 32-34 (partially)

Use of an agent which lowers levels of 11 beta-HSD1, alone or in combination with a PPAR-alpha or -gamma agonist, to promote an atheroprotective lipid profile (possibly by reducing LDL cholesterol or triglycerides or apoCIII levels, increasing HDL cholesterol or PPAR-alpha or -gamma expression or activity) and to reduce/control cardiovascular disease risk.

Pharmaceutical composition containing an agent which lowers 11beta-HSD1 levels in combination with a PPAR-gamma agonist or with a PPAR-alpha agonist (for any use).

Kit, agent or 11-beta HSD1 inhibitor containing combinations with a PPAR-gamma agonist or with a PPAR-alpha agonist (for THIS use).

2. Claims: 10, 11, 12 (partially), 23, 24, 25 (partially), 27-30 (partially), 32-34 (partially)

Use of an agent which lowers levels of 11 beta-HSD1, alone or in combination with a PPAR- alpha or -gamma agonist, to increase insulin sensitivity or to promote glucose tolerance.

Kit, agent or 11-beta HSD1 inhibitor containing combinations with a PPAR- alpha or -gamma agonist (for THIS use).

3. Claims: 35-38

Use of an agent which lowers levels of 11 beta-HSD1, alone or in combination with an appetite suppressant or an antiobesity agent, to increase metabolic rate or to prevent or reverse an undesired increase in body weight.

4. Claim : 39

A combination of an inhibitor of 11 beta-HSD 1 AND a glucocorticoid in the treatment of inflammation.

5. Claims: 40-41

Use of an agent which lowers levels of 11 beta-HSD1 to prevent side effects of glucocorticoid therapy.

6. Claims: 42-43

Use of an agent which lowers levels of 11 beta-HSD1 to reduce cholesterol storage in macrophages and combination of an inhibitor of 11beta-HSD1 with a PPAR-gamma agonist for THIS use.

7. Claims: 44-48

Use of an agent which lowers levels of 11 beta-HSD1 to reduce intrahepatic fat levels and combination of an 11 beta- HSD1 inhibitor with metformin.

The problem underlying the present invention is to find novel therapeutical agents for promoting an atheroprotective lipid profile (by acting via different mechanisms as mentioned in claims 6-11, 35-36, 40-42, 44-47) in order to reduce cardiovascular disease risks, counteract the effects of metabolic syndrome or fat/cholesterol accumulation or storage, insulin resistance, or side effects of glucocorticoid therapy.

The solution proposed is to use any agent that lowers levels of 11beta-HSD1.

The prior art shows that compounds inhibiting or lowering 11beta-HSD1 levels are well known compounds already used to treat lipid- and glucose or insulin- related disorders (see Walker et al., abstract S37 and US4920115) and some of the claimed, exemplified or mentioned compounds have already been shown to act favorably on atherogenic lipoprotein profiles (Alexandersen et al., 813-819, CAPLUS 2001:528848, Nestler et al., 3073-75 in light of Whorthwood et al., 2296-2308; and CAPLUS 1982:207991, CAPLUS 1985:553804 in light of Hult et al., 25-28).

Therefore, the favorable action of such compounds on lipid atherogenic profile and insulin sensitivity can no longer serve as a common technical relationship which could be regarded as a common special technical feature in the sense of Rule 13.2 PCT.

No further "special technical feature" in the sense of Rule 13.2 PCT can be distinguished in the present application which could form a technical relationship between the different inventions.

The present application consequently lacks unity of invention.

Each of the inventions listed is a different invention characterized by its own special technical feature, defining the contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

Searching for these different subjects would have caused major additional searching effort.

Only the first subject has been searched.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 206

Continuation of Box 3.

Although claims 13-22, 25, 30 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Further defect(s) under Article 17(2)(a):

Continuation of Box 3.

FIRST INVENTION:

* Present claims 1-4, 6-9, 12-22, 25-34, 40-43 relate to compounds defined by reference to desirable characteristic or property, namely "an agent which lowers levels of 11 beta-HSD1", "...which modulates the expression of a... gene", "...modulates 11 beta-HSD1 mRNA transcription or translation", "...inhibits 11 beta-HSD1 synthesis or activity", "which reduces (intracellular) 11 beta-HSD1 activity", "a PPAR- alpha agonist" or "a PPAR-gamma agonist", or "an inhibitor of 11 beta-HSD1".

The claims cover all products/ agents or compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such agents.

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the therapeutical uses of said agents by reference to results to be achieved ("promotion of an atheroprotective lipid profile", or by pharmacological mechanisms of action (claims 6-9, 18-22, 42). It is not possible for the skilled person to know which and how many specific diseases are included under these definitions and therefore to compare any document retrieved from the prior art with the content of the present invention.

Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Moreover, terms like "cardiovascular risk" or "cardiovascular disease", although understandable, refer to an extremely large number of possible disorders (thus (possibly unrelated) therapeutical uses). The description only supports very few aspects of such broad expressions.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and sufficiently disclosed, namely those parts relating to the compounds of claim 5 (see comment on restriction below), atherosclerosis and, concerning the PPAR agonists (in combination): fibrates (general, no specific one), pioglitazone and rosiglitazone, with due regard too the general concept of the invention (lipid profile protective against atherosclerosis).

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 206

*** Claim 5 :**

Please note that the compounds mentioned in positions 3 and 5 in this claim are structurally wrongly defined (can not exist chemically). Since no further support can be found in the description to identify which compounds could be meant (no other correctly defined compound possibly corresponding to these ones), no search was possible on these 2 compounds.

*** Claim 17:**

Since the description does not clearly and explicitly describe which compounds are included in the reference mentioned in this claim (Rule 6.2a) PCT), it is impossible to know what chemical structures are claimed herein and the claim thus lacks sufficient support and is also not clear in the sense of Article 6 PCT, to allow any search to be performed. The search on this claim was therefore only based on compounds of claim 5 (Article 17.2 PCT).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

**Annex to Form PCT/ISA/206
COMMUNICATION RELATING TO THE RESULTS
OF THE PARTIAL INTERNATIONAL SEARCH**

International Application No

PCT/GB 02/01457

1. The present communication is an Annex to the invitation to pay additional fees (Form PCT/ISA/206). It shows the results of the international search established on the parts of the international application which relate to the invention first mentioned in claims Nos.:

1-9, 12-22, 25-34

2. This communication is not the international search report which will be established according to Article 18 and Rule 43.

3. If the applicant does not pay any additional search fees, the information appearing in this communication will be considered as the result of the international search and will be included as such in the international search report.

4. If the applicant pays additional fees, the international search report will contain both the information appearing in this communication and the results of the international search on other parts of the international application for which such fees will have been paid.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WALKER B R: "CORTISOL SECRETION AND SENSITIVITY IN INSULIN RESISTANCE" JOURNAL OF ENDOCRINOLOGY, BRISTOL, GB, vol. 160, no. SUPPL, March 1999 (1999-03), page S37 XP008015770 ISSN: 0022-0795 abstract	13,16
X	HERMANOWSKI-VOSATKA A ET AL: "PPARALPHA AGONISTS REDUCE THE EXPRESSION OF 11BETAHSD1 IN THE LIVER" JOURNAL OF ENDOCRINOLOGY, BRISTOL, GB, vol. 164, March 2000 (2000-03), page 283 XP008015933 ISSN: 0022-0795 abstract 283	27
Y	HULT M ET AL: "Selective inhibition of human type 1 11beta-hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 441, no. 1, 11 December 1998 (1998-12-11), pages 25-28, XP004258864 ISSN: 0014-5793 page 27, left-hand column	1,4-6, 13,16-19
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1982 SUETINA I V: "'Changes in the lipid metabolic indices as affected by glycyrrhenate in experimental hyperlipidemia!" retrieved from STN, accession no. 1982:607991 Database accession no. 97:207991 XP002241943 abstract & NAUCHNYE DOKLADY VYSSHEI SHKOLY. BIOLOGICHESKIE NAUKI. USSR 1982, no. 8, 1982, pages 47-50, ISSN: 0470-4606</p>	1,4-6, 13,16-19
Y	<p>--- DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1984 VASILENKO YU K ET AL: "COMPARATIVE EVALUATION OF THE HYPOLIPIDEMIC EFFECT OF SOME LICORICE PREPARATIONS" retrieved from STN, accession no. 1985:553804 Database accession no. 103:153804 XP002241944 abstract & IZVESTIYA SEVERO-KAVKAZSKOGO NAUCHNOGO TSENTRA VYSSHEI SHKOLY, no. 4, 1984, pages 83-87, 1984 (RECD. 1985) ISSN: 0321-3005</p>	1,4,5
Y	<p>--- WHORWOOD C B ET AL: "REGULATION OF GLUCOCORTICOID RECEPTOR ALPHA AND BETA ISOFORMS AND TYPE I 11BETA-HYDROXYSTEROID DEHYDROGENASE EXPRESSION IN HUMAN SKELETAL MUSCLE CELLS: A KEY ROLE IN THE PATHOGENESIS OF INSULIN RESISTANCE?" JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, NEW YORK, NY, US, vol. 86, no. 5, 2001, pages 2296-2308, XP001149824 ISSN: 0021-972X abstract page 2302, right-hand column page 2303, right-hand column, last paragraph page 2306; table 3 page 2307, left-hand column</p> <p>--- -/--</p>	1,4-8, 13,16, 18-20, 27,31

**Annex to Form PCT/ISA/206
COMMUNICATION RELATING TO THE RESULTS
OF THE PARTIAL INTERNATIONAL SEARCH**

International Application No

PCT/GB 02/01457

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4 920 115 A (NESTLER JOHN E ET AL) 24 April 1990 (1990-04-24) the whole document ---	1,4,5, 13,16, 18,19
Y	MCINTOSH M ET AL: "OPPOSING ACTIONS OF DEHYDROEPIANDROSTERONE AND CORTICOSTERONE IN RATS (44405)" PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY & MEDICINE, ACADEMIC PRESS INC. NEW YORK, US, vol. 221, no. 3, July 1999 (1999-07), pages 198-206, XP001148856 ISSN: 0037-9727 page 198 -page 199, left-hand column ---	1,4-6, 13,16, 18,19
Y	NESTLER J E ET AL: "DEHYDROEPIANDROSTERONE: THE MISSING LINK BETWEEN HYPERINSULINEMIA AND ATHEROSCLEROSIS?" FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 6, no. 12, September 1992 (1992-09), pages 3073-3075, XP001148845 ISSN: 0892-6638 page 3073 ---	1,4,5, 13,16
Y	RICHARDS R J ET AL: "SERUM LEPTIN, LIPIDS, FREE FATTY ACIDS, AND FAT PADS IN LONG-TERM DEHYDROEPIANDROSTERONE-TREATED ZUCKER RATS" PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY & MEDICINE, WILLIAMS AND WILKINS, XX, vol. 223, no. 3, March 2000 (2000-03), pages 258-262, XP008015883 ISSN: 0037-9727 abstract page 260 --- -/--	1,4-6

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	<p>DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; July 2001 (2001-07) SCHWARTZ A G ET AL: "Potential therapeutic use of dehydroepiandrosterone and structural analogs." retrieved from STN, accession no. 2001:528848 Database accession no. 135:267339 XP002241945 abstract & DIABETES TECHNOLOGY & THERAPEUTICS. UNITED STATES 2001 SUMMER, vol. 3, no. 2, July 2001 (2001-07), pages 221-224, ISSN: 1520-9156</p>	<p>1,5,6, 13,16, 18,19</p>
Y	<p>--- DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 29 December 1995 (1995-12-29) MILEWICH L ET AL: "Pleiotropic effects of dietary DHEA." Database accession no. NLM8597455 XP002241946 abstract & ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. UNITED STATES 29 DEC 1995, vol. 774, 29 December 1995 (1995-12-29), pages 149-170, ISSN: 0077-8923</p>	<p>1,5,6</p>
Y	<p>--- TCHERNOF A ET AL: "Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables." ATHEROSCLEROSIS. IRELAND SEP 1997, vol. 133, no. 2, September 1997 (1997-09), pages 235-244, XP002241940 ISSN: 0021-9150 abstract page 236, left-hand column, paragraph 2 figure 2 page 238, left-hand column, paragraph 3 page 241, left-hand column, paragraph 2 page 241, right-hand column, paragraph 2</p>	<p>1,4,5</p>
	<p align="center">--- -/--</p>	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ALEXANDERSEN P ET AL: "NATURAL ANDROGENS INHIBIT MALE ATHEROSCLEROSIS A STUDY IN CASTRATED, CHOLESTEROL-FED RABBITS" CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, vol. 84, no. 7, 16 April 1999 (1999-04-16), pages 813-819, XP001149840 ISSN: 0009-7330 the whole document, especially Table 2 page 816	1,4-7, 13,16-20
Y	SMITH K J ET AL: "Peroxisomal proliferator-activated ligand therapy for HIV lipodystrophy." CLINICAL AND EXPERIMENTAL DERMATOLOGY. ENGLAND MAR 2001, vol. 26, no. 2, March 2001 (2001-03), pages 155-161, XP002241941 ISSN: 0307-6938	1,4-8,31
A	abstract page 157, left-hand column, paragraph 1 page 157, right-hand column, paragraph 2 page 158 page 159, left-hand column, paragraph 2 page 159, right-hand column, paragraph 3 - paragraph 4	9,27,32
Y	KURZMAN I D ET AL: "THE EFFECT OF DEHYDROEPIANDROSTERONE COMBINED WITH A LOW-FAT DIET IN SPONTANEOUSLY OBESE DOGS: A CLINICAL TRIAL" OBESITY RESEARCH, BATON ROUGE, LA,, US, vol. 6, no. 1, January 1998 (1998-01), pages 20-28, XP008015881 ISSN: 1071-7323 the whole document, especially the abstract	1,4,5
Y	RAO M S ET AL: "DEHYDROEPIANDROSTERONE INHIBITS DNA SYNTHESIS OF RAT HEPATOCYTES INDUCED BY PARTIAL HEPATECTOMY OF MITOGEN (CIPROFIBRATE)" CELL PROLIFERATION, OXFORD, GB, vol. 30, no. 1, 1997, pages 1-5, XP008015877 ISSN: 0960-7722 abstract	27

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HAFFA A L M ET AL: "HYPOCHOLESTEROLEMIC EFFECT OF EXOGENOUS DEHYDROEPIANDROSTERONE ADMINISTRATION IN THE RHESUS MONKEY" IN VIVO - INTERNATIONAL JOURNAL OF IN VIVO RESEARCH, XX, GB, vol. 8, no. 6, November 1994 (1994-11), pages 993-997, XP008015868 ISSN: 0258-851X the whole document	1,4,5
Y	CHANCE D S ET AL: "INVERSE RELATIONSHIP BETWEEN PEROXISOMAL AND MITOCHONDRIAL BETA-OXIDATION IN HEPG2 CELLS TREATED WITH DEHYDROEPIANDROSTERONE AND CLOFIBRIC ACID" PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY & MEDICINE, ACADEMIC PRESS INC. NEW YORK, US, vol. 205, no. 4, April 1995 (1995-04), pages 378-384, XP001148841 ISSN: 0037-9727	1,4-6, 13,16, 18,19
A	The whole document, especially abstract, Figure 1 and page 382 left column second paragraph	9,12,22, 25,27
Y	ALEXANDERSEN P ET AL: "The relationship of natural androgens to coronary heart disease in males: a review." ATHEROSCLEROSIS. IRELAND 23 AUG 1996, vol. 125, no. 1, 23 August 1996 (1996-08-23), pages 1-13, XP002241942 ISSN: 0021-9150 page 1 page 2, left-hand column, paragraph 1 page 7 page 9, right-hand column page 10	13,16
Y	GORDON G B ET AL: "REDUCTION OF ATHEROSCLEROSIS BY ADMINISTRATION OF DEHYDROEPIANDROSTERONE. A STUDY IN THE HYPERCHOLESTEROLEMIC NEW ZEALAND WHITE RABBIT WITH AORTIC INTIMAL INJURY" JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 82, no. 2, 1 August 1988 (1988-08-01), pages 712-720, XP002049299 ISSN: 0021-9738 the whole document	13,16

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; March 1989 (1989-03) ARAD Y ET AL: "Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbit." Database accession no. NLM2522296 XP002241947 abstract & ARTERIOSCLEROSIS (DALLAS, TEX.) UNITED STATES 1989 MAR-APR, vol. 9, no. 2, March 1989 (1989-03), pages 159-166, ISSN: 0276-5047</p>	13,16
A	<p>DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1968 ADLERCREUTZ H ET AL: "Studies in plasma neutral steroid sulphates, urinary 11-deoxy-17-ketosteroids and estrogens, and plasma lipids in patients with hypercholesterolemia or hyperlipemia." retrieved from STN, accession no. 1968:465726 Database accession no. 69:65726 XP002241948 abstract & ANNALES MEDICINAE EXPERIMENTALIS ET BIOLOGIAE FENNIAE. FINLAND 1968, vol. 46, no. 2, 1968, pages 165-171, ISSN: 0003-4479</p>	1,5
Y	<p>DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; November 1996 (1996-11) WALKER B R: "Abnormal glucocorticoid activity in subjects with risk factors for cardiovascular disease." Database accession no. NLM8969930 XP002241949 abstract & ENDOCRINE RESEARCH. UNITED STATES NOV 1996, vol. 22, no. 4, November 1996 (1996-11), pages 701-708, ISSN: 0743-5800</p>	1,13

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>MORTON N M ET AL: "IMPROVED LIPID AND LIPOPROTEIN PROFILE, HEPATIC INSULIN SENSITIVITY, AND GLUCOSE TOLERANCE IN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 NULL MICE"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 44, 2 November 2001 (2001-11-02), pages 41293-41300, XP001149394 ISSN: 0021-9258 the whole document</p> <p align="center">---</p>	<p>1-4, 6-9, 12-16, 18-22, 25-29</p>
P,X	<p>WO 02 02797 A (BAYER AG ;RAMAKRISHNAN SHYAM (US)) 10 January 2002 (2002-01-10) abstract page 51, line 26 - line 27 claims 13,16,17,52-57,68</p> <p align="center">---</p>	<p>1-4, 13-16</p>
P,X	<p>BERGER J ET AL: "PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA LIGANDS INHIBIT ADIPOCYTE 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 EXPRESSION AND ACTIVITY"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 16, 20 April 2001 (2001-04-20), pages 12629-12635, XP001149395 ISSN: 0021-9258 the whole document</p> <p align="center">-----</p>	<p>32</p>

Patent Family Annex

Information on patent family members

International Application No

PCT/GB 02/01457

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4920115	A	24-04-1990	NONE	

WO 0202797	A	10-01-2002	AU 7637801 A	14-01-2002
			WO 0202797 A2	10-01-2002
			EP 1309697 A2	14-05-2003
